{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,8]],"date-time":"2025-05-08T13:45:28Z","timestamp":1746711928520,"version":"3.40.5"},"reference-count":24,"publisher":"American Academy of Pediatrics (AAP)","issue":"12","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,12,1]]},"abstract":"<jats:sec>\n                  <jats:title>OBJECTIVES:<\/jats:title>\n                  <jats:p>The Finnegan Neonatal Abstinence Score (FNAS) monitors infants with neonatal abstinence syndrome (NAS), but it has been criticized for being time consuming and subjective. Many institutions have transitioned to a more straightforward screening tool, Eat, Sleep, Console (ESC), an assessment based on 3 simple observations with a focus on maximizing nonpharmacologic therapies. We aimed to compare the sensitivity and specificity of the ESC with that of the FNAS to determine if infants who needed pharmacologic therapy could potentially be missed when assessed by using ESC.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>METHODS:<\/jats:title>\n                  <jats:p>A retrospective cohort study of infants identified by International Classification of Diseases, Ninth Revision and International Classification of Diseases, 10th Revision billing codes for NAS. FNAS scores were recorded every 4 hours for the entire hospitalization. ESC proxy scores were created by using components of the FNAS that referenced eating, sleeping, and consoling. Detailed demographic and clinical data were manually extracted regarding opioid exposures and pharmacologic treatment of NAS.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>RESULTS:<\/jats:title>\n                  <jats:p>From 2013 to 2016, 423 infants \u226537 weeks\u2019 gestation had a total of 33\u2009115 FNAS scores over 921 days of observation. In total, 287 (68%) were exposed to buprenorphine, 100 (23.7%) were exposed to methadone, and 165 (39%) were pharmacologically treated. The FNAS was 94.8% sensitive and 63.5% specific for pharmacologic treatment, and the ESC proxy variables were 99.4% sensitive and 40.2% specific (P &amp;lt; .01).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>CONCLUSIONS:<\/jats:title>\n                  <jats:p>ESC proxy variables have slightly higher sensitivity compared with FNAS, suggesting that ESC use is unlikely to miss infants requiring treatment who would have been identified by FNAS. Transitioning from FNAS to ESC is not likely to impair the care of infants with NAS.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1542\/hpeds.2020-0190","type":"journal-article","created":{"date-parts":[[2020,12,1]],"date-time":"2020-12-01T14:20:46Z","timestamp":1606832446000},"page":"1053-1058","source":"Crossref","is-referenced-by-count":4,"title":["Proxy Finnegan Component Scores for Eat, Sleep, Console in a Cohort of Opioid-Exposed Neonates"],"prefix":"10.1542","volume":"10","author":[{"given":"Margaret","family":"Curran","sequence":"first","affiliation":[{"name":"Department of Family Medicine, Maine Medical Center, Portland, Maine; and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christina","family":"Holt","sequence":"additional","affiliation":[{"name":"Department of Family Medicine, Maine Medical Center, Portland, Maine; and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Arciero","sequence":"additional","affiliation":[{"name":"Department of Mathematical Sciences, University of New England, Biddeford, Maine"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"James","family":"Quinlan","sequence":"additional","affiliation":[{"name":"Department of Mathematical Sciences, University of New England, Biddeford, Maine"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Cox","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, The Barbara Bush Children\u2019s Hospital and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexa","family":"Craig","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, The Barbara Bush Children\u2019s Hospital and"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"417","published-online":{"date-parts":[[2020,12,1]]},"reference":[{"issue":"5","key":"2021120817564105500_B1","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1542\/peds.2014-3299","article-title":"Prescription opioid epidemic and infant outcomes","volume":"135","author":"Patrick","year":"2015","journal-title":"Pediatrics"},{"issue":"22","key":"2021120817564105500_B2","doi-asserted-by":"crossref","first-page":"2118","DOI":"10.1056\/NEJMsa1500439","article-title":"Increasing incidence of the neonatal abstinence syndrome in U.S. neonatal ICUs","volume":"372","author":"Tolia","year":"2015","journal-title":"N Engl J Med"},{"issue":"2","key":"2021120817564105500_B3","doi-asserted-by":"crossref","DOI":"10.1542\/peds.2013-3524","article-title":"Neonatal abstinence syndrome","volume":"134","author":"Kocherlakota","year":"2014","journal-title":"Pediatrics"},{"issue":"31","key":"2021120817564105500_B4","doi-asserted-by":"crossref","first-page":"799","DOI":"10.15585\/mmwr.mm6531a2","article-title":"Incidence of neonatal abstinence syndrome \u2013 28 states, 1999\u20132013","volume":"65","author":"Ko","year":"2016","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"1","key":"2021120817564105500_B5","doi-asserted-by":"crossref","first-page":"F2","DOI":"10.1136\/fn.88.1.F2","article-title":"Treatment of neonatal abstinence syndrome","volume":"88","author":"Johnson","year":"2003","journal-title":"Arch Dis Child Fetal Neonatal Ed"},{"key":"2021120817564105500_B6","doi-asserted-by":"crossref","first-page":"204","DOI":"10.3389\/fped.2017.00204","article-title":"Judging the neonatal abstinence syndrome assessment tools to guide future tool development: the use of clinimetrics as opposed to psychometrics","volume":"5","author":"Westgate","year":"2017","journal-title":"Front Pediatr"},{"key":"2021120817564105500_B7","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1111\/j.1360-0443.2012.04039.x","article-title":"Differences in the profile of neonatal abstinence syndrome signs in methadone- versus buprenorphine-exposed neonates","volume":"107","author":"Gaalema","year":"2012","journal-title":"Addiction"},{"issue":"3","key":"2021120817564105500_B8","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1097\/JPN.0000000000000043","article-title":"An overview of clinical tools used to assess neonatal abstinence syndrome","volume":"28","author":"Orlando","year":"2014","journal-title":"J Perinat Neonatal Nurs"},{"issue":"1","key":"2021120817564105500_B9","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1016\/j.drugalcdep.2013.06.004","article-title":"Time to initiation of treatment for neonatal abstinence syndrome in neonates exposed in utero to buprenorphine or methadone","volume":"133","author":"Gaalema","year":"2013","journal-title":"Drug Alcohol Depend"},{"issue":"4","key":"2021120817564105500_B10","first-page":"353","article-title":"Neonatal abstinence syndrome, pharmacotherapy and developmental outcome","volume":"8","author":"Kaltenbach","year":"1986","journal-title":"Neurobehav Toxicol Teratol"},{"issue":"4","key":"2021120817564105500_B11","doi-asserted-by":"crossref","first-page":"226","DOI":"10.2174\/1574887112666170816144818","article-title":"Neonatal abstinence syndrome management: a review of recent evidence","volume":"12","author":"Grossman","year":"2017","journal-title":"Rev Recent Clin Trials"},{"issue":"24","key":"2021120817564105500_B12","doi-asserted-by":"crossref","first-page":"2320","DOI":"10.1056\/NEJMoa1005359","article-title":"Neonatal abstinence syndrome after methadone or buprenorphine exposure","volume":"363","author":"Jones","year":"2010","journal-title":"N Engl J Med"},{"issue":"6","key":"2021120817564105500_B13","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1111\/j.1751-486X.2007.00243.x","article-title":"Methadone and buprenorphine treatment during pregnancy: what are the effects on infants?","volume":"11","author":"Pritham","year":"2007","journal-title":"Nurs Womens Health"},{"issue":"9","key":"2021120817564105500_B14","doi-asserted-by":"crossref","first-page":"e016176","DOI":"10.1136\/bmjopen-2017-016176","article-title":"Simplification of the Finnegan Neonatal Abstinence Scoring System: retrospective study of two institutions in the USA","volume":"7","author":"Gomez Pomar","year":"2017","journal-title":"BMJ Open"},{"issue":"4","key":"2021120817564105500_B15","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1097\/YCO.0000000000000334","article-title":"Neonatal abstinence syndrome: where are we, and where do we go from here?","volume":"30","author":"Brandt","year":"2017","journal-title":"Curr Opin Psychiatry"},{"issue":"4","key":"2021120817564105500_B16","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1002\/ajh.24307","article-title":"Maternal opioid dose is associated with neonatal abstinence syndrome in children born to women with sickle cell disease","volume":"91","author":"Shirel","year":"2016","journal-title":"Am J Hematol"},{"issue":"1","key":"2021120817564105500_B17","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1186\/s13063-016-1666-9","article-title":"A core outcome set for neonatal abstinence syndrome: study protocol for a systematic review, parent interviews and a Delphi survey","volume":"17","author":"Kelly","year":"2016","journal-title":"Trials"},{"issue":"5","key":"2021120817564105500_B18","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1111\/ajad.12388","article-title":"Psychometric assessment of the Neonatal Abstinence Scoring System and the MOTHER NAS Scale","volume":"25","author":"Jones","year":"2016","journal-title":"Am J Addict"},{"issue":"1","key":"2021120817564105500_B19","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1186\/1940-0640-9-19","article-title":"Review of the assessment and management of neonatal abstinence syndrome","volume":"9","author":"Bagley","year":"2014","journal-title":"Addict Sci Clin Pract"},{"issue":"1","key":"2021120817564105500_B20","doi-asserted-by":"crossref","first-page":"47","DOI":"10.5055\/jom.2009.0006","article-title":"The opioid-exposed newborn: assessment and pharmacologic management","volume":"5","author":"Jansson","year":". 2009","journal-title":"J Opioid Manag"},{"issue":"1","key":"2021120817564105500_B21","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1542\/hpeds.2017-0128","article-title":"A novel approach to assessing infants with neonatal abstinence syndrome","volume":"8","author":"Grossman","year":"2018","journal-title":"Hosp Pediatr"},{"issue":"6","key":"2021120817564105500_B22","doi-asserted-by":"crossref","first-page":"e20163360","DOI":"10.1542\/peds.2016-3360","article-title":"An initiative to improve the quality of care of infants with neonatal abstinence syndrome","volume":"139","author":"Grossman","year":"2017","journal-title":"Pediatrics"},{"issue":"8","key":"2021120817564105500_B23","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1001\/jamapediatrics.2018.1307","article-title":"Comparison of safety and efficacy of methadone vs morphine for treatment of neonatal abstinence syndrome: a randomized clinical trial","volume":"172","author":"Davis","year":"2018","journal-title":"JAMA Pediatr"},{"issue":"1","key":"2021120817564105500_B24","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1097\/ANC.0b013e318241bd73","article-title":"Implementing practice guidelines and education to improve care of infants with neonatal abstinence syndrome","volume":"12","author":"Lucas","year":"2012","journal-title":"Adv Neonatal Care"}],"container-title":["Hospital Pediatrics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/publications.aap.org\/hospitalpediatrics\/article-pdf\/10\/12\/1053\/813113\/hpeds_2020-0190.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/publications.aap.org\/hospitalpediatrics\/article-pdf\/10\/12\/1053\/813113\/hpeds_2020-0190.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,8]],"date-time":"2021-12-08T19:25:32Z","timestamp":1638991532000},"score":1,"resource":{"primary":{"URL":"https:\/\/publications.aap.org\/hospitalpediatrics\/article\/10\/12\/1053\/25940\/Proxy-Finnegan-Component-Scores-for-Eat-Sleep"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,12,1]]},"references-count":24,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2020,12,1]]},"published-print":{"date-parts":[[2020,12,1]]}},"URL":"https:\/\/doi.org\/10.1542\/hpeds.2020-0190","relation":{},"ISSN":["2154-1663","2154-1671"],"issn-type":[{"type":"print","value":"2154-1663"},{"type":"electronic","value":"2154-1671"}],"subject":[],"published":{"date-parts":[[2020,12,1]]}}}